Cellectis SA (CLLS)
1.87
-0.04
(-2.09%)
USD |
NASDAQ |
Nov 15, 16:00
1.86
-0.01
(-0.53%)
After-Hours: 20:00
Cellectis Research and Development Expense (TTM): 94.63M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 94.63M |
| June 30, 2024 | 89.87M |
| March 31, 2024 | 88.56M |
| December 31, 2023 | 87.65M |
| September 30, 2023 | 84.12M |
| June 30, 2023 | 88.89M |
| March 31, 2023 | 92.32M |
| December 31, 2022 | 97.50M |
| September 30, 2022 | 97.24M |
| June 30, 2022 | 107.73M |
| March 31, 2022 | 113.25M |
| December 31, 2021 | 117.65M |
| September 30, 2021 | 109.93M |
| June 30, 2021 | 95.71M |
| March 31, 2021 | 87.42M |
| December 31, 2020 | 77.14M |
| September 30, 2020 | 94.13M |
| June 30, 2020 | 95.62M |
| Date | Value |
|---|---|
| March 31, 2020 | 98.18M |
| December 31, 2019 | 91.96M |
| September 30, 2019 | 82.92M |
| June 30, 2019 | 80.02M |
| March 31, 2019 | 72.64M |
| December 31, 2018 | 76.53M |
| September 30, 2018 | 75.83M |
| June 30, 2018 | 77.43M |
| March 31, 2018 | 77.99M |
| December 31, 2017 | 79.18M |
| September 30, 2017 | 78.67M |
| June 30, 2017 | 73.81M |
| March 31, 2017 | 76.93M |
| December 31, 2016 | 78.73M |
| September 30, 2016 | 75.76M |
| June 30, 2016 | 78.51M |
| March 31, 2016 | 71.13M |
| December 31, 2015 | 57.79M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
77.14M
Minimum
Dec 2020
117.65M
Maximum
Dec 2021
95.48M
Average
94.38M
Median
Research and Development Expense (TTM) Benchmarks
| Edap TMS SA | 8.741M |
| DBV Technologies SA | 83.21M |
| Genfit SA | -- |
| Adaptimmune Therapeutics PLC | 143.17M |
| Akari Therapeutics PLC | 8.848M |